• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And More

    6/18/24 12:48:24 AM ET
    $CYBN
    $GRAM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Basic Industries
    Get the next $CYBN alert in real time by email

    As the premier gathering of top entrepreneurs and investors took place on Monday in New Jersey, we thought it would be a good time to scroll through the latest leadership changes in the cannabis and psychedelics industries.

    Cybin Inc. (NYSE:CYBN) (Cboe CA: CYBN) a clinical-stage biopharmaceutical company that develops new and innovative next-generation psychedelic-based treatment options, announced recently that Dr. Atul R. Mahableshwarkar M.D., DLFAPA, opted to join the company as senior vice president of clinical development.

    Dr. Mahableshwarkar agreed to lead the development of the CYB003 program, Cybin's proprietary deuterated psilocybin analog which has received U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for the adjunctive treatment of major depressive disorder.

    Board Updates At Six Cannabis Companies

    The annual general meeting of shareholders  of Curaleaf Holdings, Inc. (TSX:CURA) (OTCQX:CURLF) was held on Friday, during which the following experts were elected as directors:

    • Boris Jordan;
    • Joseph Lusardi;
    • Dr. Jaswinder Grover;
    • Karl Johansson;
    • Peter Derby;
    • Mitchell Kahn;
    • Shasheen Shah; and
    • Michelle Bodner.

    Cannabis powerhouse Planet 13 Holdings Inc. (CSE:PLTH) (OTCQX:PLNH) named David Loop, the former CEO of VidaCann LLC who has spent his entire career in the horticulture industry, to its board of directors, last week. The Las Vegas company acquired VidaCann May for $63.4 million. The new addition comes on the heels of its shareholders electing five experts to serve on its board.

    Charlotte’s Web Holdings, Inc. (TSX:CWEB) (OTCQX:CWBHF) announced the results from its 2024 annual general and special meeting of shareholders held on June 13, during which the following nominees were elected to serve on the company's board of directors:

    • Jonathan Atwood;
    • Matthew McCarthy;
    • Angela McElwee;
    • William Morachnick;
    • Jared Stanley; and
    • Maureen Usifer.

    California cannabis company Flora Corporation's (Cboe Canada: GRAM) shareholders elected the following experts to its board of directors:

    • Laurie Holcomb;
    • Michael W. Lau;
    • Heather Molloy;
    • Jeffery Sears;
    • Al Foreman; and
    • Mark Castaneda.

    Canadian producer and distributor of cannabis products Entourage Health Corp. (TSXV:ENTG) (OTCQX:ETRGF) (FSE: 4WE) announced that shareholders overwhelmingly approved all proposed resolutions at its annual general meeting of shareholders held last week, including electexting the following nominees to its board of directors:

    • George Scorsis;
    • Gail Paech;
    • Bruce Croxon; and
    • Jason Alexander.

    TILT Holdings Inc. (NEO: TILT) (OTCQB:TLLTF), provider of cannabis business solutions that include inhalation technologies, cultivation, manufacturing, processing, brand development and retail, also announces the results of the 2024 annual general meeting of its shareholders. The following nominees were elected to serve as the company's directors:

    • John Barravecchia;
    • Tim Conder;
    • Adam Draizin;
    • George Odden; and
    • Arthur Smuck.

    Get the next $CYBN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYBN
    $GRAM

    CompanyDatePrice TargetRatingAnalyst
    Cybin Inc.
    $CYBN
    3/13/2025$35.00Buy
    Guggenheim
    Cybin Inc.
    $CYBN
    11/22/2021$8.00 → $10.00Buy
    HC Wainwright & Co.
    Cybin Inc.
    $CYBN
    11/19/2021Buy → Hold
    Maxim Group
    Cybin Inc.
    $CYBN
    10/5/2021$7.00Outperform
    Oppenheimer
    Cybin Inc.
    $CYBN
    8/26/2021$9.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CYBN
    $GRAM
    SEC Filings

    View All

    SEC Form 6-K filed by Cybin Inc.

    6-K - CYBIN INC. (0001833141) (Filer)

    1/5/26 4:51:28 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form CERT filed by Cybin Inc.

    CERT - CYBIN INC. (0001833141) (Filer)

    1/2/26 11:06:32 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-A12B filed by Cybin Inc.

    8-A12B - CYBIN INC. (0001833141) (Filer)

    1/2/26 6:14:27 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYBN
    $GRAM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq

    Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company's ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market ("Nasdaq") and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists ("NSAs"), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma's NSA in Phase 3 clinical development,

    1/5/26 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin Initiates At-The-Market Equity Program of up to US$100 Million

    Cybin Inc. (NYSE:CYBN) (Cboe Canada CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has launched an at-the-market equity program (the "ATM Program") to allow Cybin to issue and sell up to US$100,000,000 of common shares in the capital of the Company (the "Shares") from treasury to the public, from time to time, through Cantor Fitzgerald and Co. and Cantor Fitzgerald Canada Corporation (together the "Agents"). All the Shares sold under the ATM Program will be sold in transactions that are deemed to be "at-the-market

    12/30/25 3:33:00 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

    Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market ("Nasdaq") from the NYSE American LLC ("NYSE American"). The Company expects that its common shares will cease trading on the NYSE American at market close on January 4, 2026 and commence trading on Nasdaq at market open on January 5, 2026. Concurrent with the commencement of trading on Nasdaq, the Company will no longer trade under the ticker symbol "CYBN" and instead will trade under

    12/18/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYBN
    $GRAM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Foreman Albert John converted options into 8,375 shares, increasing direct ownership by 9% to 98,198 units (SEC Form 4)

    4 - Gold Flora Corp. (0001876945) (Issuer)

    3/31/25 3:55:55 PM ET
    $GRAM
    Military/Government/Technical
    Basic Industries

    SEC Form 4 filed by Chief Legal Officer Feldman Brian

    4 - Gold Flora Corp. (0001876945) (Issuer)

    3/12/25 2:53:50 PM ET
    $GRAM
    Military/Government/Technical
    Basic Industries

    SEC Form 3 filed by new insider Feldman Brian

    3 - Gold Flora Corp. (0001876945) (Issuer)

    3/12/25 2:52:45 PM ET
    $GRAM
    Military/Government/Technical
    Basic Industries

    $CYBN
    $GRAM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Cybin with a new price target

    Guggenheim initiated coverage of Cybin with a rating of Buy and set a new price target of $35.00

    3/13/25 7:34:44 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Cybin with a new price target

    HC Wainwright & Co. reiterated coverage of Cybin with a rating of Buy and set a new price target of $10.00 from $8.00 previously

    11/22/21 6:24:49 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin downgraded by Maxim Group

    Maxim Group downgraded Cybin from Buy to Hold

    11/19/21 8:09:52 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYBN
    $GRAM
    Leadership Updates

    Live Leadership Updates

    View All

    Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

    Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market ("Nasdaq") from the NYSE American LLC ("NYSE American"). The Company expects that its common shares will cease trading on the NYSE American at market close on January 4, 2026 and commence trading on Nasdaq at market open on January 5, 2026. Concurrent with the commencement of trading on Nasdaq, the Company will no longer trade under the ticker symbol "CYBN" and instead will trade under

    12/18/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin Announces Results of Annual Meeting of Shareholders

    Cybin Inc. (NYSE:CYBN) (Cboe CA: CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 18, 2025 (the "Meeting"). There were 90 shareholders represented in person or by proxy at the Meeting holding 11,264,212 common shares, representing 48.92% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below:

    8/18/25 5:30:00 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

    - Strategic Partnership Agreements promote collaboration and aligned incentives across sites, enhancing operational efficiency and improving site performance and patient recruitment - - Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from depression symptoms for 12 months in 71% of MDD patients - - Patient dosing continues in APPROACH, Cybin's first pivotal Phase 3 study of CYB003 for the adjunctive treatment for Major Depressive Disorder ("MDD") - - Second Phase 3 study, EMBRACE, is expected to begin mid-2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform

    4/23/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYBN
    $GRAM
    Financials

    Live finance-specific insights

    View All

    Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

    - Company to host conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025, to provide a business update and report financial results for its second quarter ended September 30, 2025. CONFERENCE CALL DETAILS: Dial-in: 800-245-3047 (U.S. toll free) or 203-518-9765 (International) Conference ID: CYBN1113 Webcast: R

    11/6/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

    - 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses of CYB003 - - Robust, long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score compared to baseline at 12 months after two 16 mg doses of CYB003 - - Findings validate dosing regimen and confirm that CYB003's effects are highly durable and offer sustained relief for MDD patients - - CYB003 continues to be well-tolerated and demonstrates an excellent safety profile - - Cybin's Phase 3 PARADIGM TM multinational pivotal program evaluating the efficacy and safety of CYB003 has been initiated - - Company to

    11/18/24 7:00:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gold Flora Reports Third Quarter 2024 Financial Results

    Reports $32.6 Million in Q3 2024 Revenue and Adjusted Gross Profit of $21.1 Million, Representing a 65% Adjusted Gross Margin Achieves Positive Adjusted EBITDA of $2.8 Million Recent Cultivation Investments Delivered 20% Improvement in Q3 2024 Flower Harvest Yields Compared to Q1 2024 Conference Call to be Held November 14, 2024, at 6:00 p.m. (Eastern Time) COSTA MESA, Calif., Nov. 14, 2024 /CNW/ - Gold Flora Corporation, ("Gold Flora" or the "Company") (CBOE: GRAM) (OTCQB:GRAM) a leading vertically-integrated California cannabis company, announced its financial results for the three month period ("Q3 2024"). All amounts are expressed in U.S. dollars.

    11/14/24 5:00:00 PM ET
    $GRAM
    Military/Government/Technical
    Basic Industries

    $CYBN
    $GRAM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cybin Inc.

    SC 13G - CYBIN INC. (0001833141) (Subject)

    12/3/24 5:23:26 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cybin Inc.

    SC 13G/A - CYBIN INC. (0001833141) (Subject)

    11/14/24 7:51:22 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cybin Inc.

    SC 13G/A - CYBIN INC. (0001833141) (Subject)

    11/14/24 6:55:13 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care